Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.40 |
| ▸ | INCENP | Q9NQS7 | 3/20 | 0.40 |
| ▸ | RBP4 | P02753 | 8/20 | 0.39 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL343047 | 1.00 | AURKA (0.40) | AURKAAURKBINCENPRBP4RET | |
| SCHEMBL343433 | 0.95 | RET (0.40) | AURKAAURKBINCENPRBP4RET | |
| SCHEMBL343434 | 0.95 | RET (0.40) | AURKAAURKBINCENPRBP4RET | |
| SCHEMBL343435 | 0.95 | RET (0.40) | AURKAAURKBINCENPRBP4RET | |
| Trifluoroacetic Acid SCHEMBL342171 | 0.94 | AURKA (0.40) | AURKAAURKBINCENPRBP4RET | |
| Trifluoroacetic Acid SCHEMBL474405 | 0.94 | AURKA (0.40) | AURKAAURKBINCENPRBP4RET | |
| Trifluoroacetic Acid SCHEMBL342173 | 0.94 | AURKA (0.40) | AURKAAURKBINCENPRBP4RET | |
| SCHEMBL342172 | 0.91 | AURKA (0.37) | AURKAAURKBINCENPRBP4RET | |
| SCHEMBL343153 | 0.89 | KMT2A (0.40) | AURKAAURKBINCENPRBP4PPARG | |
| SCHEMBL343154 | 0.89 | KMT2A (0.40) | AURKAAURKBINCENPRBP4PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367690-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | VERTEX PHARMACEUTICALS INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015969-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | AURKA 1/4885AURKB 3/4885INCENP 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.